Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Delfraissy

Showing results (171-180 of 207) with videos related to

Pageof 21
Sort By:
Gastroenterologie Clinique Et Biologique|January 1, 1996
[Liver, biliary tracts and human immunodeficiency virus infection. 1:q liver, HIV and hepatitis B, C and D viruses]D A Vuitton, P Chossegros, S Bresson-Hadni, et al.
European Journal of Immunology|December 18, 2001
Human microglial cells express a functional IL-12 receptor and produce IL-12 following IL-12 stimulationY Taoufik, M G de Goër de Herve, J Giron-Michel, et al.
European Journal of Immunology|June 1, 1996
Triggering of CD23b antigen by anti-CD23 monoclonal antibodies induces interleukin-10 production by human macrophagesN Dugas, I Vouldoukis, P Bécherel, et al.
Journal Francais D'Ophtalmologie|December 2, 1998
[Incidence and evaluation of viral retinitis in patients infected with the HIV virus and treated with HIV protease inhibitors]M Labetoulle, C Goujard, E Frau, et al.
Gastroenterologie Clinique Et Biologique|April 1, 1987
Reduction of the observed prevalence of so-called non-A non-B hepatitis using sensitive markers of HBV and herpes viruses infectionsT Poynard, J F Delfraissy, S Naveau, et al.
The Journal of Infection|January 9, 2007
Constant mitochondrial DNA levels in blood leukocytes of patients enrolled in a NRTI-free therapeutic trial (BIKS-2 study)B Amellal, C Allavena, E André-Garnier, et al.
HIV Medicine|September 17, 2004
Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohortV Schiffer, C Deveau, L Meyer, et al.
The Journal of Infectious Diseases|August 7, 1999
CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study GroupsL Meyer, M Magierowska, J B Hubert, et al.
The Journal of Antimicrobial Chemotherapy|September 18, 2014
HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavirK A Sutherland, J Ghosn, J Gregson, et al.
AIDS (London, England)|September 8, 2001
Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patientsM L Gougeon, C Rouzioux, I Liberman, et al.
Pageof 21

Showing results (171-180 of 207) with videos related to

Sort By:
Pageof 21
Gastroenterologie Clinique Et Biologique|January 1, 1996
[Liver, biliary tracts and human immunodeficiency virus infection. 1:q liver, HIV and hepatitis B, C and D viruses]D A Vuitton, P Chossegros, S Bresson-Hadni, et al.
European Journal of Immunology|December 18, 2001
Human microglial cells express a functional IL-12 receptor and produce IL-12 following IL-12 stimulationY Taoufik, M G de Goër de Herve, J Giron-Michel, et al.
European Journal of Immunology|June 1, 1996
Triggering of CD23b antigen by anti-CD23 monoclonal antibodies induces interleukin-10 production by human macrophagesN Dugas, I Vouldoukis, P Bécherel, et al.
Journal Francais D'Ophtalmologie|December 2, 1998
[Incidence and evaluation of viral retinitis in patients infected with the HIV virus and treated with HIV protease inhibitors]M Labetoulle, C Goujard, E Frau, et al.
Gastroenterologie Clinique Et Biologique|April 1, 1987
Reduction of the observed prevalence of so-called non-A non-B hepatitis using sensitive markers of HBV and herpes viruses infectionsT Poynard, J F Delfraissy, S Naveau, et al.
The Journal of Infection|January 9, 2007
Constant mitochondrial DNA levels in blood leukocytes of patients enrolled in a NRTI-free therapeutic trial (BIKS-2 study)B Amellal, C Allavena, E André-Garnier, et al.
HIV Medicine|September 17, 2004
Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohortV Schiffer, C Deveau, L Meyer, et al.
The Journal of Infectious Diseases|August 7, 1999
CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study GroupsL Meyer, M Magierowska, J B Hubert, et al.
The Journal of Antimicrobial Chemotherapy|September 18, 2014
HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavirK A Sutherland, J Ghosn, J Gregson, et al.
AIDS (London, England)|September 8, 2001
Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patientsM L Gougeon, C Rouzioux, I Liberman, et al.
Pageof 21